NEW YORK, N.Y.—July 31, 2007
The award recognizes Dr. Salmon’s innovative research into the pathogenesis of organ damage in systemic lupus erythematosus and other disorders of the immune system. Her research crosses the boundary between basic and clinical disciplines. Experiments performed in models of human disease elucidate the mechanisms and mediators of the organ damage and provide the information necessary to develop new treatments for patients. Most recently, her laboratory has explored the reasons for the high incidence of pregnancy loss in women with lupus, and particularly in those who have the antiphospholipid syndrome.
Dr. Salmon organized and directs a multicenter study funded by the National Institutes of Health (NIH) to translate her findings in laboratory animals with lupus-associated pregnancy loss to patients. The PROMISSE (Predictors of pRegnancy Outcome: bioMarkers In antiphospholipid antibody Syndrome and Systemic lupus Erythematosus) Study is a prospective observational study of 400 pregnant patients enrolled at six major clinical centers that seeks to identify biomarkers that predict a poor pregnancy outcome and find targets for treatment.
“Hospital for Special Surgery could not be prouder of Jane Salmon, M.D., not only because she has received the prestigious Nachman Prize, but also because of her uniquely productive physician-scientist career that led to this international recognition,” said Stephen A. Paget, M.D., physician-in-chief and chairman of the Division of Rheumatology, Hospital for Special Surgery. “Dr. Salmon is the first woman who has received this award in a decade, a fitting honor for a scientist who has dedicated her life’s work to improving the longevity and quality of life of women with systemic lupus erythematosus and the antiphospholipid syndrome.
“Her investigations have spanned the spectrum of research, from basic to translational to clinical. They have been transformative, profoundly changing our paradigms of disease causation and treatment. She is the model, modern, rheumatologic scientist, one who moves back and forth effortlessly and tirelessly from the bedside to the bench to alter the ways in which we think about autoimmune disease and their pathogeneses,” he noted.
Based on the experience of two decades in lupus research, Dr. Salmon formed a hypothesis that challenged conventional understanding and embarked on a project that contradicted accepted thinking about the antiphospholipid syndrome, a disorder frequently associated with lupus and characterized by pregnancy complications and thrombosis. She was convinced that inflammation, rather than thrombosis, is the event that leads to pregnancy loss in patients with the disorder.
The series of papers that proved her hypothesis and defined the cascade of events responsible for pregnancy failure is considered one of the seminal achievements of recent research in rheumatology.
Dr. Salmon received a bachelor of arts degree, magna cum laude, from New York University in 1972, and a doctor of medicine degree from Columbia University, College of Physicians and Surgeons, in 1978, where she was the first woman chosen for the Medical Scientist Training Program. She completed a residency in Medicine at New York Hospital and fellowship in Rheumatic Diseases at New York Hospital and Hospital for Special Surgery, New York.
She currently holds the rank of professor of Medicine, Weill Cornell Medical College, New York, and senior scientist and attending physician, Hospital for Special Surgery. She is an attending physician at New York Presbyterian Hospital and a professor in the Graduate Program in Immunology, Weill Graduate School of Medical Sciences of Cornell University.
Dr. Salmon is the recipient of numerous academic awards and honors, including election to membership in Phi Beta Kappa and Alpha Omega Alpha, receiving the Henry Christian Award for Excellence in Research from the American Federation for Clinical Research, and being named one of 100 Young Women of Promise by Good Housekeeping Magazine.
She has been invited to deliver numerous named lectureships throughout the world, including the Edmund L. Dubois, M.D., Memorial Lectureship Award of the American College of Rheumatology and, most recently, the Eric Bywaters Memorial Lecture at Imperial College of London.
A consistent participant in scientific advisory and review panels in her discipline, Dr. Salmon has served on the advisory committee for NIH Lupus Multiplex Registry and Repository, was chair of the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) Special Grants Review Committee, is currently chair of the Alliance for Lupus Research Study Section, and is chair of the Protocol Review Committee, Rare Diseases Clinical Research Network, National Center for Research Resources, NIH. She is a member of the Board of Directors of the American College of Rheumatology and served as chair of its Committee on Research.
Dr. Salmon is the author of more than 100 peer-reviewed publications and of many textbook and monograph chapters. She is currently co-editor of the main journal in her subspecialty, Arthritis and Rheumatism, and a member of the editorial board of the journal Lupus.
Dr. Salmon’s research interests also include the mechanism of premature cardiovascular disease in patients with lupus and rheumatoid arthritis and the genetic basis for differences in renal disease severity in lupus patients.
In addition to NIH support for the PROMISSE Study, she recently received a five-year renewal grant from NIH/NIAMS to study the mechanism of antiphospholipid antibody-induced pregnancy loss. She is also the principal investigator for a National Institute of Allergy and Infectious Diseases-funded grant to study the mechanisms of recurrent miscarriage.
The Carol-Nachman Prize was established in 1972 to honor outstanding innovative research work in the field of rheumatology. Each year, one or two scientists from around the world are recognized in Wiesbaden with this honor.
About HSS | Hospital for Special Surgery
HSS is the world’s leading academic medical center focused on musculoskeletal health. At its core is Hospital for Special Surgery, nationally ranked No. 1 in orthopedics (for the eighth consecutive year) and No. 3 in rheumatology by U.S. News & World Report (2017-2018). Founded in 1863, the Hospital has one of the lowest infection rates in the country and was the first in New York State to receive Magnet Recognition for Excellence in Nursing Service from the American Nurses Credentialing Center four consecutive times. The global standard total knee replacement was developed at HSS in 1969. An affiliate of Weill Cornell Medical College, HSS has a main campus in New York City and facilities in New Jersey, Connecticut and in the Long Island and Westchester County regions of New York State. In 2017 HSS provided care to 135,000 patients and performed more than 32,000 surgical procedures. People from all 50 U.S. states and 80 countries travelled to receive care at HSS. In addition to patient care, HSS leads the field in research, innovation and education. The HSS Research Institute comprises 20 laboratories and 300 staff members focused on leading the advancement of musculoskeletal health through prevention of degeneration, tissue repair and tissue regeneration. The HSS Global Innovation Institute was formed in 2016 to realize the potential of new drugs, therapeutics and devices. The culture of innovation is accelerating at HSS as 130 new idea submissions were made to the Global Innovation Institute in 2017 (almost 3x the submissions in 2015). The HSS Education Institute is the world’s leading provider of education on the topic on musculoskeletal health, with its online learning platform offering more than 600 courses to more than 21,000 medical professional members worldwide. Through HSS Global Ventures, the institution is collaborating with medical centers and other organizations to advance the quality and value of musculoskeletal care and to make world-class HSS care more widely accessible nationally and internationally.